Celcuity (CELC) stock was up more than 113% pre-bell Monday after the company said results from a phase 3 trial showed that a combination of gedatolisib, palbociclib, and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone in patients with locally advanced or metastatic breast cancer.
Mill City Ventures III (MCVT) shares were 61% higher, extending Friday's rally.
TruGolf (TRUG) stock was up 22% following a 5.8% loss on Friday.
22nd Century Group (XXII) shares were 23% higher, adding to a 4.1% increase in the previous session.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。